OncoMark - Research

OncoMark is actively involved in multiple research projects to identify and validate biomarkers in clinical samples for cancer progression and drug response. Specifically, OncoMark participates in six EU Framework Programme 7 (FP7) research programmes in which protein biomarker discovery plays a key role. These include projects focused on breast cancer, prostate cancer, colorectal cancer and melanoma skin cancer. A list of the projects are detailed below.

'SYS-MEL' image

SYS-MEL

The incidence of melanoma continues to increase dramatically. Melanoma is increasing in men more rapidly than any other malignancy, while in women it is the second most rapid increasing malignancy, after lung cancer. The lifetime risk of developing melanoma is estimated to be as high as one in 55. In our Industry-Academia Partnerships and Pathways (IAPP) project, SYS-MEL, we are collectively developing molecular assays to aid in the clinical management of melanoma. » read more

 
'APO-DECIDE' image

APO-DECIDE

Colorectal cancer (CRC) has among the highest cancer mortality rate worldwide, with over 608,700 deaths per year. Annually, over one million new cases are diagnosed worldwide. APO-DECIDE will develop and validate systems-based biomarkers for apoptosis susceptibility. » read more

 
'FAST-PATH' image

FAST-PATH

Prostate cancer is the second most common form of cancer in men. Around 910,000 cases of prostate cancer were recorded in 2008, accounting for nearly 14% of all new cancer cases in men. In the same year, there were over 250,000 deaths from the disease and it is predicted that the number of cases will almost double to 1.7 million by 2030. The FAST-PATH research programme will contribute significantly to our understanding of the mechanisms and pathology underlying prostate cancer. » read more

 
'AngioPredict' image

AngioPredict

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females in the developed world. Currently, an important treatment for these patients is the drug AvastinĀ® (bevacizumab), which inhibits tumour blood vessel formation and thus prevents tumour growth. AngioPredict will identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. » read more

 
'Target Melanoma' image

Target Melanoma

Malignant melanoma is a highly aggressive disease, with minimal treatment options for patients that present in the later stages. In our Industry-Academia Partnerships and Pathways (IAPP) project, Target-Melanoma, we are investigating the molecular basis underlying this difficult-to-treat disease, focusing on the discovery of new biomarkers (i.e. indicators) or potential targets for therapy. » read more

 
'Angiotox' image

Angiotox

AngioTox is an EU FP7-funded IAPP project integrating expertise in biomarker discovery, histopathology, multi-modality in vivo imaging and automated image analysis. » read more

 
'RATHER' image

RATHER

RATHER is a consortium project funded by the European Commission's 7th Framework Programme of Research and Development. The project will focus on several key aspects of breast cancer research, and will involve the combined efforts of six universities and two biomedical companies. RATHER commenced in January 2011, and will operate for a period of five years » read more